Minomic is transforming cancer diagnostics with MiCheck® Prostate, a revolutionary blood test that detects significant prostate cancer with 95% sensitivity—reducing false positives by 50% and cutting unnecessary biopsies and healthcare costs. With U.S. sales launched through a CLIA lab, we’re targeting 3,000 tests and $2M revenue next year, paving the way for rapid scaling in a $2B+ market.